Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1

Conditions

Multiple Myeloma 74Lymphoma, Follicular 20Lymphoma, Large B-Cell, Diffuse 19Neoplasms, Plasma Cell 11Lymphoma, Mantle-Cell 8Lymphoma, B-Cell, Marginal Zone 8Recurrence 7Smoldering Multiple Myeloma 6Lymphoma, B-Cell 6Leukemia, Lymphocytic, Chronic, B-Cell 6Neoplasms 5Lymphoma 5Lymphoma, Non-Hodgkin 4Burkitt Lymphoma 3Plasmacytoma 2Neuroblastoma 2Neoplasm, Residual 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Neurologic Manifestations 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, AIDS-Related 1Leukemia, Plasma Cell 1Leukemia 1Histiocytosis, Langerhans-Cell 1

Interventions

X-Rays 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Magnetic Resonance Spectroscopy 5Specimen Handling 4Biopsy 4ulixertinib 2tipifarnib 2selpercatinib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Cyclophosphamide 2tazemetostat 1palbociclib 1olaparib 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1Vemurafenib 1Thiotepa 1Tacrolimus 1Sirolimus 1Pharmacogenomic Variants 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Melphalan 1Lenalidomide 1LY3023414 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Histiocytosis, Langerhans-Cell × Lenalidomide × Clear all
NCT02523040 2025-12-10

Lenalidomide for Adult Histiocyte Disorders

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
12 enrolled 14 charts
MyeloidSarcoma

Histiocytosis, Langerhans-Cell, Erdheim-Chester Disease, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡